Comparison of 1550nm Fractional Laser Alone Versus in Combination With Microneedling for the Treatment of Acne Scars
Status unconfirmed · Not applicable
Conditions studied: Acne Scars
In brief
Acne scarring is an unfortunate consequence of inflammatory acne vulgaris that often leads to significant cosmetic and psychosocial impacts. Although there have been many advances in the treatment of acne scarring, it remains one of the greatest challenges in cosmetic and laser dermatology. There have been a multitude of studies establishing the efficacy of non-ablative fractional laser therapy for the treatment of atrophic acne scars, and it is widely regarded as one of the best available treatments. More recently, there has been a renewed interest in controlled, non-thermal dermal injury via microneedling devices in the treatment of atrophic acne scars. Where there is a gap in the literature, however, is in the evaluation of the combination of non-ablative fractional laser resurfacing with microneedling in the treatment of atrophic acne scars. The investigators' study will compare the safety and efficacy of using non-ablative fractional laser versus a combination of microneedling and non-ablative fractional laser for atrophic acne scars using a randomized, double-blind, split-face study. The investigators' aim is to further elucidate the pathogenesis of acne scarring and the best approaches for treatment. In doing so, the investigators will study a combination approach to this complex problem in order to better serve future patients.
Key facts
- Study ID
- NCT03901417
- Run by
- Massachusetts General Hospital
- People needed
- 10
- Starts
- 2019-06-01
- Expected to finish
- 2020-12-31
- Last updated by the study team
- 2020-01-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- All gender patients
- Age older than 18 years
- Fitzpatrick skin types I-III
- Facial acne scarring of grades III-IV
- Both sides of the face should have similar amount and severity of acne scarring
You may not qualify if…
- History of keloidal scarring
- Localized or active infection in the treatment region
- Immunodeficiency disorders
- Porphyria or light sensitivity
- Connective tissue disorders.
- Pregnant or nursing
- Recent isotretinoin use within the past 6 months
- Renal Disease
- Allergies to lidocaine, tetracaine, valacyclovir
Where it is running
- Massachusetts General Hospital — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.